Lupin generic Hyzaar, Cozaar get final FDA approval
The brand products had combined annual sales of $1.6bn in the US, based on IMS sales data for the 12 months ended June 2010. Mumbai, India-based Lupin Limited
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Jevtana, a microtubule inhibitor, is approved in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-based treatment regimen.